Dermatology Portfolio Pathway: a complete guide for senior doctors.

The dermatology route in brief

Dermatology reaches the Specialist Register by the same two routes as every specialty: a Certificate of Completion of Training (CCT) at the end of UK training, or the Portfolio Pathway for doctors who have not completed a UK approved programme but can demonstrate equivalent knowledge, skills and experience. If you are new to the route, start with the complete guide to the Portfolio Pathway; this article assumes that grounding and focuses on what is specific to dermatology.

What surprises applicants about dermatology is how procedural it is. The specialty is genuinely broad, spanning medical and inflammatory disease, skin cancer, and a substantial surgical component, alongside multidisciplinary working with oncologists, histopathologists and allied surgical specialties. An applicant whose evidence is all clinic letters and no validated procedural work has an incomplete application, however deep the medical dermatology looks. That shapes how the whole portfolio should be planned.

The spine of your application is the General Medical Council (GMC) Specialty Specific Guidance (SSG) for Dermatology, read alongside the 2021 dermatology curriculum and the dedicated Portfolio Pathway guidance from the British Association of Dermatologists (BAD). Read all three before gathering anything. We explain how to read an SSG in general in the SSG guide.

Not a dual application, but the internal medicine base still matters

Here is a genuine relief for many applicants. Unlike gastroenterology or respiratory medicine, dermatology is a Group 2 specialty: it is decoupled from the ongoing acute medical take, so it is not a dual application with General Internal Medicine. You do not have to evidence an ongoing GIM commitment or the unselected acute take. That removes a substantial block of evidence that the medical specialties carry.

What you do still need is the medical foundation underneath dermatology. The curriculum and SSG expect you to demonstrate medical knowledge and its application to the level of completion of internal medicine stage 1 training, evidenced through the general and clinical capabilities of the curriculum. In other words, sound general medical competence is assumed and must be shown, but it is the foundation rather than a parallel specialty.

This is one of the clearer cases where understanding the specialty's training structure changes how you plan. Because there is no GIM half, the procedural and skin cancer evidence carries proportionally more weight. We cover the wider question of when specialties are dual, and when they are not, in the guide on dual certification.

The SCE and the qualification requirement

To apply via the Portfolio Pathway in a CCT specialty such as dermatology, you need a relevant specialist qualification, or at least six months of continuous specialist training in dermatology gained outside a UK programme. For dermatology, the clearest qualification is the Specialty Certificate Examination (SCE) in Dermatology, and many successful applicants hold it. The SCE is the most direct way to evidence the specialty knowledge base to the standard expected.

If you do not hold the SCE, you are not automatically excluded, but you must demonstrate equivalent specialist training and a knowledge base evidenced across the curriculum. The exact wording of the eligibility requirement is defined in the SSG, so read it carefully and check whether the qualification you hold satisfies it. Do not assume; this is the kind of eligibility detail that is worth confirming with the GMC before you invest years in evidence.

The 2021 curriculum and its 13 capabilities

The 2021 dermatology curriculum is built on Capabilities in Practice (CiPs): high-level descriptions of what a day-one consultant can do. There are 13 in total, and knowing the structure helps because it is the framework your evidence will be mapped against.

The seven specialty capabilities cover the whole shape of the specialty: general and inflammatory dermatology, acute and emergency dermatology, liaison and community dermatology, skin tumours and skin cancer, procedural dermatology, paediatric dermatology, and other specialist aspects such as teledermatology, dermoscopy, photobiology and cutaneous allergy. Your evidence has to demonstrate each at consultant level. The underlying logic of CiPs, and how to map evidence to them, sits in the Capabilities in Practice guide, within the four GMC domains.

Skin surgery and procedural dermatology

If gastroenterology is decided by endoscopy, dermatology is decided by procedural evidence and skin cancer working. Procedural dermatology is one of the specialty capabilities, and it is the area applicants from clinic-heavy backgrounds most often underbuild. You need to evidence safe, independent competence across the core procedures, validated and observed, not simply asserted.

Skin cancer is the other defining strand, and the two are linked through the multidisciplinary team. UK skin cancer care runs through local and specialist skin cancer multidisciplinary teams, and consultant dermatologists are central to them. Evidence of genuine participation in the skin cancer MDT, two-week-wait pathway working, and the management of melanoma and non-melanoma skin cancer is exactly what assessors look for, and it is hard to assemble convincingly from a system that does not run skin cancer care the way the NHS does. Where you have an advanced surgical interest, Mohs and advanced dermatological surgery has its own recognised curriculum you can reference.

One strand sits between the medical and the urgent and is easy to under-evidence: acute and emergency dermatology. Erythroderma, severe drug reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, eczema herpeticum, and the dermatological emergencies that present to acute services are a distinct specialty capability, and they are where dermatology meets acute medicine. Alongside this, liaison and inpatient dermatology, advising other teams on the skin manifestations of systemic disease, is part of consultant practice. Evidence from on-call advice, inpatient referrals and the management of dermatological emergencies demonstrates that you can handle the unwell patient, not only the elective clinic. Capture it as you would any other evidence: specific cases, your role, the decisions you led, and a short reflection mapped to the relevant capability. It is exactly the kind of evidence that distinguishes a consultant-level portfolio from a competent specialty-trainee one.

What evidence you need

The procedural and skin cancer evidence is specialty-specific, but a complete application maps across the whole curriculum using the same evidence types as every specialty. The table below is the working inventory.

The cross-specialty evidence types each repay being built deliberately. We cover the workhorses in depth: multi-source feedback, workplace-based assessments, audit, and structured reports and referees. An audit of your own skin cancer pathway, for example two-week-wait timeliness or excision margin completeness, is particularly efficient, because it doubles as governance evidence and as proof of engagement with skin cancer quality.

Subspecialty breadth

Dermatology is broad, and assessors look for evidence across its main areas rather than depth in only one. A portfolio that is all skin surgery and no inflammatory dermatology, or all medical dermatology and no procedural work, looks unbalanced against a curriculum built for general specialty practice. Think in three broad areas and make sure each is genuinely represented.

Modern medical dermatology also carries a substantial governance dimension that is worth evidencing explicitly. Systemic immunosuppression and biologic therapy for conditions such as psoriasis, atopic eczema and hidradenitis suppurativa involve monitoring protocols, shared decision-making, multidisciplinary input and registries. Demonstrating that you initiate and monitor these therapies safely, within local and national governance, shows consultant-level judgement rather than just knowledge. It is a strand assessors value and one that maps neatly across several capabilities at once, from clinical management to safety and teamwork.

If you have a defined special interest, whether that is advanced surgery, cutaneous allergy, paediatric dermatology or photobiology, lean into it as evidence of consultant-level depth, provided the general breadth is also there. The guide on special interest areas covers how to evidence one, and the dedicated guide on dermatology procedures and biopsies goes deeper on the procedural logbook itself.

A realistic timeline

Most candidates take two to four years from starting evidence collection to Specialist Register entry. Dermatology applicants often need time to build a validated skin surgery logbook and to evidence skin cancer MDT working alongside the breadth of medical dermatology, particularly if their current post is clinic-heavy with limited surgical lists. The procedural evidence is the usual rate-limiting step.

The processing time after submission is the same as for any specialty: the GMC's published guidance is six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months from submission to outcome, on top of the evidence-building years. The full sequence is in the timeline guide, and what happens after you submit in the after-submission guide.

As ever, the single biggest variable is your post. A department with consultant-delivered minor operations lists, a functioning skin cancer MDT, dermoscopy training and supportive seniors who will act as verifiers makes this achievable. A post that is all general clinic with no surgical sessions makes the procedural evidence very hard to build, however able you are. That is worth weighing honestly, and sometimes worth acting on.

Why dermatology applications stall

Related guides

Dermatology sits within the wider library of specialism overviews and the cross-cutting evidence guides. If you are still choosing or confirming your specialty, the guide on choosing your specialty helps. The full set of specialism overviews:

Build these alongside your application

The procedural and skin cancer evidence is specialty-specific, but the rest of the portfolio draws on the same cross-cutting evidence types as every application. Build these in parallel.

Frequently asked questions

Do I need General Internal Medicine for the dermatology Portfolio Pathway?

No. Dermatology is a Group 2 specialty, decoupled from the ongoing acute medical take, so it is not a dual application with GIM in the way gastroenterology or respiratory medicine are. You do, however, need to demonstrate medical knowledge to the level of completion of Internal Medicine stage 1 training, evidenced through the general and clinical capabilities of the curriculum. So you need sound general medical foundations, but not a separate GIM application or ongoing acute take evidence.

Do I need the SCE in Dermatology for the Portfolio Pathway?

You need a relevant specialist qualification in dermatology, such as the Specialty Certificate Examination (SCE), or at least six months of continuous specialist training in dermatology gained outside a UK programme. The SCE is the clearest way to evidence the knowledge base, and many successful applicants hold it. If you do not, you must show equivalent specialist training and a knowledge base evidenced across the curriculum. Check the current wording in the GMC Specialty Specific Guidance, because the exact requirement is defined there.

How much skin surgery do I need to evidence?

There is no single fixed number. Procedural dermatology is one of the specialty capabilities, so you must evidence competence in skin surgery and dermatological procedures: excisions, biopsies, curettage and cautery, cryotherapy and the management of complications, with histological correlation. A validated logbook showing breadth and depth, with workplace-based assessments and evidence of independent practice, is what matters, not a raw count. Procedural competence is a significant part of a consultant dermatologist's role and assessors expect to see it clearly.

What evidence does a dermatology Portfolio Pathway application need?

Evidence mapped to the 13 curriculum capabilities: a skin surgery and procedural logbook, skin cancer multidisciplinary team participation, clinical case mix across medical and inflammatory dermatology, workplace-based assessments, multi-source feedback, audit and quality improvement, teaching and CPD, and structured reports from senior colleagues. You also evidence the internal medicine stage 1 knowledge base. Everything should be recent, mapped to the relevant capability, and organised so an assessor can navigate it easily.

Can I apply if I trained in dermatology overseas?

Yes, but direct applications from overseas are challenging because the evidence must mirror UK dermatology practice, including skin cancer pathway working and procedural dermatology to UK standards. You need a relevant specialist qualification or at least six months of continuous specialist training in dermatology, and the British Association of Dermatologists provides specific guidance. For many internationally trained dermatologists the realistic route is a UK post first, building the procedural and skin cancer MDT evidence from inside the system.

How long does the dermatology Portfolio Pathway take?

Most candidates take two to four years from starting evidence collection to Specialist Register entry. Dermatology applicants often need time to build a validated skin surgery logbook and to evidence skin cancer MDT working and the breadth of medical dermatology. Once submitted, the GMC takes six to twelve months to process before the Royal College evaluation, with the decision after that. Plan for roughly twelve to eighteen months of process time on top of the evidence-building years.